Results 181 to 190 of about 346,427 (358)

Things We Do for No Reason: Failing to consider primary aldosteronism in the initial evaluation of hypertension, hypertensive urgency, and hypertensive emergency

Journal of Hospital Medicine, EarlyView.
Abstract Hypertension is frequently treated as essential hypertension. However, secondary causes of hypertension should be considered, because distinct treatments are used for different causes of hypertension. Primary aldosteronism is considered a candidate for the most common cause of secondary hypertension.
Michael C. Shih, Tessa R. Lavorgna, Prerna Dogra, Christina N. Hirner, Kristen Payne   +4 more
wiley   +1 more source

The Adrenergic Nerves and Gastrointestinal Smooth Muscle Function

, 1968
James Christensen
openalex   +1 more source

Safety and Effect of 12‐Month Ecopipam Treatment in Pediatric Patients with Tourette Syndrome

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Tourette syndrome (TS) is a chronic neurodevelopmental tic disorder with a considerable quality of life (QOL) burden. Objectives The goal was to determine the long‐term safety, tolerability, and clinical effects of ecopipam, a first‐in‐class dopamine D1 receptor antagonist, for TS.
Donald L. Gilbert, David J.B. Kim, Meredith M. Miller, Sarah D. Atkinson, George B. Karkanias, Frederick E. Munschauer, Stephen P. Wanaski, Timothy M. Cunniff   +7 more
wiley   +1 more source

β-Adrenergic receptors mediate sex differences in vasodilation but not sympathetic-mediated vasoconstriction during hypoxia. [PDF]

Am J Physiol Heart Circ Physiol
Jacob DW, Shariffi B, Bond BJ, Boyes NG, Martin SA, Gonsalves AM, Harper JL, Bostick BP, Limberg JK.   +8 more
europepmc   +1 more source

Investigating Dopamine Replacement–Associated Fluctuations in Cognition and Mood in Cognitively Unimpaired Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor fluctuations, characterized by variability in mood and cognition, are prevalent in advanced Parkinson's disease (PD), but less is known about these fluctuations in early PD. Objective The objective was to characterize fluctuations in cognition and mood in early PD without cognitive impairment.
Abhimanyu Mahajan, Christopher B. Morrow, Joseph Seemiller, Kelly A. Mills, Gregory M. Pontone   +4 more
wiley   +1 more source

Adrenergic pathways in glycine-mediated feeding behavior: Evidence from layer chickens. [PDF]

Poult Sci
Zarei H, Kashefi F, Hasani K.
europepmc   +1 more source

Prevention of Epinephrine-Halothane Arrhythmias by Adrenergic α-Receptor Blockade [PDF]

, 1964
John Hess
openalex   +1 more source

Management of Anxiety in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Anxiety is a common, distressing, hard‐to‐diagnose and hard‐to‐treat symptom in Parkinson's disease. No formal guidelines exist to assist management. Objective We provide a pragmatic guide to detecting and managing anxiety in Parkinson's disease.
Alex J. Berry, Harry Costello, Silvia Jesús, Gary Price, Ashwani Jha   +4 more
wiley   +1 more source

Deletion of PPARα in mouse brown adipocytes increases their De Novo Lipogenesis. [PDF]

Mol Metab
Batrow PL, Caspar-Bauguil S, Rochet N, Gautier N, Rousseau AS, Maret M, Rekima S, Mouisel E, Van Obberghen E, Roux CH, Guillou H, Postic C, Wolfrum C, Langin D, Amri EZ, Mothe-Satney I.   +15 more
europepmc   +1 more source

Recent Developments in the Optical Control of Adrenergic Signaling

Medicinal Research Reviews, EarlyView.
ABSTRACT Adrenoceptors (ARs) play a vital role in various physiological processes and are key therapeutic targets. The advent of optical control techniques, including optogenetics and photopharmacology, offers the potential to modulate AR signaling with precise temporal and spatial resolution. In this review, we summarize the latest advancements in the
Shuang Shi, Yangzhi Cao, Maikel Wijtmans, Henry F. Vischer, Rob Leurs   +4 more
wiley   +1 more source